Cargando…
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models
Antibody drug conjugates represent an important class of anti-cancer drugs in both solid tumors and hematologic cancers. Here, we report preclinical data on the anti-tumor activity of the first-in-class antibody drug conjugate MEN1309/OBT076 targeting CD205. The study included preclinical in vitro a...
Autores principales: | Gaudio, Eugenio, Tarantelli, Chiara, Spriano, Filippo, Guidetti, Francesca, Sartori, Giulio, Bordone, Roberta, Arribas, Alberto J., Cascione, Luciano, Bigioni, Mario, Merlino, Giuseppe, Fiascarelli, Alessio, Bressan, Alessandro, Mensah, Afua Adjeiwaa, Golino, Gaetanina, Lucchini, Renzo, Bernasconi, Elena, Rossi, Davide, Zucca, Emanuele, Stussi, Georg, Stathis, Anastasios, Boyd, Robert S., Dusek, Rachel L., Bisht, Arnima, Attanasio, Nickolas, Rohlff, Christian, Pellacani, Andrea, Binaschi, Monica, Bertoni, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604571/ https://www.ncbi.nlm.nih.gov/pubmed/33131247 http://dx.doi.org/10.3324/haematol.2019.227215 |
Ejemplares similares
-
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
por: Spriano, Filippo, et al.
Publicado: (2022) -
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis
por: Arribas, Alberto J., et al.
Publicado: (2022) -
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance
por: Tarantelli, Chiara, et al.
Publicado: (2018) -
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
por: Hicks, Stuart W., et al.
Publicado: (2019) -
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response
por: Mensah, Afua Adjeiwaa, et al.
Publicado: (2014)